Tag Archives: KPTI

Jefferies Group Analysts Reduce Earnings Estimates for Karyopharm Therapeutics (KPTI)

Karyopharm Therapeutics (NASDAQ:KPTI) – Investment analysts at Jefferies Group lowered their Q2 2018 earnings estimates for Karyopharm Therapeutics in a research note issued on Tuesday, May 15th. Jefferies Group analyst M. Raycroft now forecasts that the company will post earnings per share of ($0.77) for the quarter, down from their prior estimate of ($0.62). Jefferies Group has a “Buy” rating on the stock. Jefferies Group also issued estimates for Karyopharm Therapeutics’ Q3 2018 earnings at ($0.71) EPS, Q4 2018 earnings at ($0.78) EPS, FY2018 earnings at ($3.03) EPS, FY2019 earnings at ($2.66) EPS, FY2020 earnings at ($1.05) EPS, FY2021 earnings at ($0.74) EPS and FY2022 earnings at $0.73 EPS.

Get Karyopharm Therapeutics alerts:

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Thursday, May 10th. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.11). The company had revenue of $10.00 million for the quarter, compared to analyst estimates of $4.59 million.

Several other research firms have also recently weighed in on KPTI. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Karyopharm Therapeutics in a research note on Thursday. Zacks Investment Research raised shares of Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday. BidaskClub raised shares of Karyopharm Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday. Canaccord Genuity lifted their price objective on shares of Karyopharm Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday, March 12th. Finally, Cantor Fitzgerald set a $18.00 price objective on shares of Karyopharm Therapeutics and gave the stock a “buy” rating in a research report on Thursday, March 15th. Two research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. Karyopharm Therapeutics has a consensus rating of “Buy” and a consensus price target of $21.10.

Karyopharm Therapeutics opened at $19.08 on Friday, Marketbeat reports. Karyopharm Therapeutics has a 1-year low of $18.33 and a 1-year high of $18.89.

In other news, CEO Michael Kauffman sold 10,000 shares of the business’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $14.79, for a total value of $147,900.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Mansoor Raza Mirza sold 2,500 shares of the business’s stock in a transaction dated Monday, March 12th. The shares were sold at an average price of $17.01, for a total transaction of $42,525.00. Following the completion of the sale, the director now directly owns 2,500 shares of the company’s stock, valued at approximately $42,525. The disclosure for this sale can be found here. In the last three months, insiders sold 67,000 shares of company stock valued at $1,021,320. 14.71% of the stock is currently owned by company insiders.

Hedge funds have recently bought and sold shares of the stock. Teacher Retirement System of Texas acquired a new position in Karyopharm Therapeutics in the fourth quarter valued at about $115,000. MetLife Investment Advisors LLC acquired a new position in Karyopharm Therapeutics in the fourth quarter valued at about $146,000. Two Sigma Investments LP raised its stake in Karyopharm Therapeutics by 76.8% in the fourth quarter. Two Sigma Investments LP now owns 24,220 shares of the company’s stock valued at $233,000 after purchasing an additional 10,520 shares in the last quarter. UBS Group AG raised its stake in Karyopharm Therapeutics by 761.8% in the first quarter. UBS Group AG now owns 19,632 shares of the company’s stock valued at $264,000 after purchasing an additional 17,354 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale acquired a new position in Karyopharm Therapeutics in the first quarter valued at about $269,000. 62.65% of the stock is owned by institutional investors and hedge funds.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.

Earnings History and Estimates for Karyopharm Therapeutics (NASDAQ:KPTI)

Your Daily Pharma Scoop: IRWD Division, Jazz sNDA, Siga Adcomm

Analysis focus: IRWD

Ironwood Pharma (NASDAQ:IRWD) is going to split into two separate companies, both publicly traded, with one focusing on commercialization and the other on R&D. This move will happen in the first half of 2019 and be tax free to current shareholders.

Ironwoods linzess, which was approved 6 years ago in irritable bowel syndrome with constipation and for treatment of chronic idiopathic constipation. Recently, as we know, Synergy Pharmas (NASDAQ:SGYP) Trulance got approved by the FDA for the same indications. Now, according to some sources, Trulance is a safer drug than Linzess. However, Trulance has not been able to take off as well as investors had assumed, although it has put a dent in the prospects of Linzess.

Linzess is marketed by Allergan (NYSE:AGN), which has considerable marketing prowess. Now, this bid to separate IRWD into two divisions probably owes itself to one reason – that after 6 years of approval, IRWD has still not been able to become profitable. As the announcement of this news says, the commercial division of IRWD, which is focused on Linzess, ..is expected to be profitable in 2019. That means, if you reduce the R&D expenses from the total cash burn of the company, then it could become profitable on Linzess revenues. At least, that seems to be the idea.

The other division will do R&D on cyclic guanosine monophosphate pharmacology to advance a pipeline of treatments for rare and serious diseases led by mid-stage candidates praliciguat and olinciguat. This will be the division that will look for future treatments to bring to market as Linzess completes its market cycle.

For SGYP investors, what is interesting to note here is that this move seems aimed to make Linzess profitable for at least a part of the company. That is to say, the old Ironwood has to shed the more cash burning part of it – the R&D section – to make this happen.

This could mean, either, that Trulance is really taking over some of Linzess traditional market, and/or the market itself is not sustaining enough for Linzess to make enough money to cover Ironwoods entire cash requirements, although IRWD has managed to reduce OpEx drastically.

The first idea is a good thing for Synergy investors; the second is a sobering conclusion of how just getting a product approved but without proper money and marketing management can still ruin the future prospects of a company.

In related news, IRWD released earnings results for Q1 and missed both by EPS and by revenue, despite seeing a 32% increase in revenue Y/Y.

Stocks in News: Analysis of JAZZ, SIGA

Jazz Pharma submits U.S. marketing application for expanded use of Xyrem

Discussion: Jazz Pharmas (NASDAQ:JAZZ) Xyrem was first approved in 2002 to treat cataplexy in narcolepsy and for EDS in narcolepsy. This expanded use sNDA will increase the scope of Xyrem to include pediatric patients. The market isnt much because Age of onset for narcolepsy typically occurs in the second decade of life; however, diagnosis can occur 1016 years later on average.

FDA Ad Com backs SIGA’s smallpox treatment

Discussion: Naturally occuring smallpox was eradicated in 1980, but SIGA technologies (NASDAQ:SIGA) TPOXX (tecovirimat) is an antiviral oral treatment targeting smallpox when used as a biological weapon, for which no medicine exists as of now. Vaccination is risky and not efficient for people with low exposure risks, especially for an eradicated disease. However, the market for this new drug candidate will be for defense purposes. PDUFA is August 8.

In other news

Karyopharm (NASDAQ:KPTI), which was highlighted in yesterdays scoop, has now come up with a $125mn stock offering, taking the stock down 3%.

Mallinckrodts (NYSE:MNK) stannsoporfin has an adcomm on Thursday for elevated blood bilirubin in neonates (at least 35 weeks’ gestational age) with indicators of hemolysis (rupture of red blood cells) who are at risk of developing severe hyperbilirubinemia (excess bilirubin in the blood). This is a small market.

Medtronics (NYSE:MDT) Deep Brain Stimulation therapy has been approved by the FDA as adjunctive therapy for adult patients with partial onset seizues in drug resistant epilepsy.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.


Top 10 High Tech Stocks To Watch For 2018

DOL Wins Fiduciary Rule Case in Texas

DOL Will Need Time to Deliver on Trumps Order

DOJ Tells Texas Judge to Postpone Ruling on Fiduciary Rule

The recruiting scene is following the stock market and, unlike the weather on the East Coast, continues to heat up.

Morgan Stanley said it added the NRS Wealth Management Group from Merrill Lynch on Jan. 20. The team consists of three financial advisors who have combined yearly fees and commissions of nearly $4.6 million and about $600 million in client assets.

Wirehouses and other large broker-dealers seem cautiously optimistic on what President Trump will do next with the fiduciary rule.

You are signed up!

ThinkAdvisor’s TechCenter is an educational resource designed to give you a competitive edge by keeping you abreast of new tech innovations and need-to-know information that can be applied to your business. Resources The secret to benefits without barriers

This complimentary report discusses those powerful benefits in detail along with a wide range of planning applications.

Top 10 High Tech Stocks To Watch For 2018: Ultra Clean Holdings, Inc.(UCTT)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Friday, technology shares fell 3.59 percent. Meanwhile, top losers in the sector included Ultra Clean Holdings Inc (NASDAQ: UCTT), down 5 percent, and Brooks Automation, Inc (NASDAQ: BRKS), down 10 percent.

  • [By Lisa Levin]

    In trading on Monday, technology shares fell 0.65 percent. Meanwhile, top losers in the sector included Ultra Clean Holdings Inc (NASDAQ: UCTT), down 4 percent, and Mitek Systems, Inc. (NASDAQ: MITK), down 7 percent.

Top 10 High Tech Stocks To Watch For 2018: Coach, Inc.(COH)

Advisors’ Opinion:

  • [By Jeremy Bowman]

    Fashion is already a tough play on the stock market. Once-popular labels likeMichael Kors(NYSE:KORS) andCoach(NYSE:COH) have tumbled recently as their brands seem to have become diluted in a highly competitive handbag market. The problem with investing in stocks like these is that often what’s in style one year is on the discount rack just a few years later.

  • [By Ben Levisohn]

    Coach (COH) has risen 1.1% to $37.76 after getting upgraded to Buy from Hold at Evercore ISI.

    Illumina (ILMN) has dropped 2.4% to $156.22 after beating fourth-quarter earnings forecasts but offering first-quarter revenue guidance that fell short of analyst expectations.

  • [By Ben Levisohn]

    Kate Spade (KATE) caught a bounce on Wednesday when the Wall Street Journalreported that it was actively seeking a buyer. Since then, we’ve learned that the fashion accessories retailer looks set to auction itself off to the highest bidder, with the process potentially beginning next month, with bidders potentially including Coach (COH) and Michael Kors (KORS). In a note today, SunTrust Robinson Humphrey analystPamela Quintiliano and team contend that Kate Spade could fetch as much as $23 a share:

Top 10 High Tech Stocks To Watch For 2018: ServiceNow, Inc.(NOW)

Advisors’ Opinion:

  • [By Michael A. Robinson]

    You’d be hard pressed to find a quieter tech leader than ServiceNow Inc. (NYSE: NOW).

    That’s likely because hardly anyone pays attention to IT services companies besides their customers. After all, the digital “plumbing” found in corporate campuses and skyscrapers is not as exciting as artificial intelligence, cryptocurrencies… or flying cars.

  • [By Lee Jackson]

    ServiceNow Inc. (NYSE: NOW) had a director at the enterprise cloud-based solutions provider selling stock last week. Frederic Luddy sold a total of 101,500 sharesat $76.84 apiece. The total for the sale was $7,799,376. The consensus price target is $93.41, and shares were trading last Friday at $76.02.

Top 10 High Tech Stocks To Watch For 2018: Karyopharm Therapeutics Inc.(KPTI)

Advisors’ Opinion:

  • [By Chris Lange]

    Karyopharm Therapeutics Inc. (NASDAQ: KPTI) was raised to a Buy rating from Hold, and the price target was increased to $12 from $9, at Jefferies. The firm said its call is based on its future revenue opportunity in multiple myeloma. Itsshares most recently closed at $10.62, with a consensus price target of $16.30 and a 52-week range of $4.83 to $19.41.

Top 10 High Tech Stocks To Watch For 2018: Insulet Corporation(PODD)

Advisors’ Opinion:

  • [By Brian Feroldi]

    Shares of Insulet Corporation(NASDAQ:PODD), a medical device company primarily focused on diabetes,rose by as much as 11% in afternoon trading on Friday.

  • [By Chris Lange]

    Insulet Corp. (NASDAQ: PODD) released its most recent earnings report after the markets closed on Wednesday. The company posted a net loss of $0.12 per share on $130.5 million in revenue, versus consensus estimates that called for a net loss of $0.08 per share on $125.3 million in revenue. Analysts weighed in on the firm:

  • [By Peter Graham]

    A long term performance chart shows MannKind Corporation having once been a highflyerwhile the performance of large cap insulin and diabetes stockNovo Nordisk A/S (NYSE: NVO) has fallen off and small cap Insulet Corporation (NASDAQ: PODD) has actually performed better:

Top 10 High Tech Stocks To Watch For 2018: Actinium Pharmaceuticals, Inc.(ATNM)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Actinium Pharmaceuticals Inc (NYSE: ATNM) were down 24 percent to $1.29. Actinium priced 8 million shares at $1.25 per share.

    Shineco Inc (NASDAQ: TYHT) was down, falling around 32 percent to $19.50. On Wednesday, Shineco priced IPO at $4.50 per share.

Top 10 High Tech Stocks To Watch For 2018: Crestwood Equity Partners LP(CEQP)

Advisors’ Opinion:

  • [By Lisa Levin]

    Crestwood Equity Partners LP (NYSE: CEQP) shares shot up 45 percent to $18.54 following the announcement of a new joint venture with Consolidated Edison, Inc. (NYSE: ED). Subsidiaries of both companies entered into an agreement on Thursday to form a joint venture in which they will jointly own and develop Crestwood’s existing natural gas pipeline and storage business in norther Pennsylvania and southern New York.

Top 10 High Tech Stocks To Watch For 2018: Murphy Oil Corporation(MUR)

Advisors’ Opinion:

  • [By Ben Levisohn]

    It wasn’t just Marathon that got clipped as the eight worst-performing stocks in the S&P 500 came from the energy sector, including Murphy Oil (MUR), which fell 6.7% to $25.87, Devon Energy (DVN), which slid 6.5% to $40.72, and Chesapeake Energy (CHK), which stumbled 6.1% to $4.94. No surprise, then, that the Energy Select Sector SPDR ETF (XLE) slumped 2.6% to $69.65.

  • [By David Tristan Liu]

    Murphy USA (MUSA) first caught my attention after Southeastern Asset Management acquired a massive stake ($668mm) in its former parent company Murphy Oil Corporation (MUR) in Q1 2013. One thing about Murphy Oil Corporation I noticed after an initial glance through their 10-K and annual report was its ownership of a valuable fuel and convenience retailer segment with high ROIC, valuable real estate, low CAPEX requirements, and relatively decent growth prospects that was under-followed and whose underlying value was concealed by the parent company’s core production and exploration business.

  • [By Ben Levisohn]

    Oil stocks responded immediately to Opec–Murphy Oil (MUR) was our Hot Stock on Wednesday when the deal was reached, while Transocean (RIG) was our Hot Stock on Monday even before an announcement was made–Southwestern is only now catching a bid, a bid that pushed its market capitalization up to $6.5 billion.

  • [By Matt Egan]

    Before Tuesday, Big Oil’s credit ratings had been left largely intact by S&P. But with oil sinking back to $30 a barrel, the ratings firm took action by downgrading Chevron (CVX), EOG Resources (EOG), Apache (APA), Devon Energy (DVN), Hess (HES), Marathon Oil (MRO), Murphy Oil (MUR), Continental Resources (CLR) and Southwestern Energy (SWN).

  • [By Ben Levisohn]

    Today, it was all about oil afterOPEC “reached an understanding” on capping oil production. And that made Murphy Oil (MUR) the hottest stock in the S&P 500.

Top 10 High Tech Stocks To Watch For 2018: Actuant Corporation(ATU)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Flexing the barbell strategy to balance Safe Havens with more cyclical exposures. In our view, industrials investors should be positioning their portfolio with a barbell strategy, with half of the exposure in Safe Havens like General Electric, Xylem (XYL), Danaher, Honeywell International, Roper Technologies (ROP), and AMETEK (AME), and the other half selectively in the cyclical names that are better positioned today, such as Pentair, HD Supply Holdings (HDS),Actuant (ATU), Atkore International Group (ATKR), Ingersoll-Rand, and Eaton (ETN). We still believe risk-reward is mostly balanced and that the macro will remain choppy into 2017, supporting a positioning in the defensive names. But if investor sentiment improves on not-worse news and earnings results, the more cyclical names could fare better.

  • [By Monica Gerson]

    Actuant Corporation (NYSE: ATU) is estimated to report its quarterly earnings at $0.18 per share on revenue of $267.64 million.

    Jabil Circuit, Inc. (NYSE: JBL) is projected to post its quarterly earnings at $0.60 per share on revenue of $4.50 billion.

  • [By Monica Gerson]

    Actuant Corporation (NYSE: ATU) is projected to report its quarterly earnings at $0.18 per share on revenue of $267.64 million. Actuant shares dropped 3.73 percent to close at $22.98 yesterday.

Top 10 High Tech Stocks To Watch For 2018: Veritiv Corporation(VRTV)

Advisors’ Opinion:

  • [By Lisa Levin] Related CRMD Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher 12 Biggest Mid-Day Gainers For Tuesday CorMedix's (CRMD) CEO Khoso Baluch on Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
    Related BIOA Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher Mid-Morning Market Update: Markets Edge Higher; Tiffany Earnings Top Estimates BioAmber (BIOA) Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
    CorMedix Inc. (NYSE: CRMD) shares fell 27.5 percent to $1.50 after the company reported Q4 results and issued a business update.
    Bioamber Inc (NYSE: BIOA) shares tumbled 23.6 percent to $2.40. BioAmber reported FY16 adjusted loss of $1.07 per share on revenue of $8.3 million.
    The Medicines Company (NASDAQ: MDCO) shares dipped 20.9 percent to $41.62.
    Innocoll Holdings PLC (NASDAQ: INNL) shares fell 20.3 percent to $1.49. Innocoll posted a narrower-than-expected quarter loss, but revenue missed estimates. Stifel Nicolaus downgraded Innocoll from Buy to Hold.
    Rosetta Genomics Ltd. (USA) (NASDAQ: ROSG) shares declined 20.3 percent to $3.83. On Thursday, Rosetta Genomics disclosed a 1-for-12 reverse stock split.
    Esperion Therapeutics Inc (NASDAQ: ESPR) shares dropped 19.9 percent to $23.76. Esperion Therapeutics shares have jumped 106.19 percent over the past 52 weeks, while the S&P 500 index has gained 16.70 percent in the same period.
    AmTrust Financial Services Inc (NASDAQ: AFSI) tumbled 18.3 percent to $17.65. AmTrust Financial disclosed that it will delay its annual report filing for the fiscal year ended December 31, 2016.
    Qualstar Corporation (NASDAQ: QBAK) slipped 17.7 percent to $6.85. Qualstar reported a Q4 loss of $0.20 per share on revenue of $2.2 milli